News

Press Releases

  • March 1, 2024
CorFlow Infusion SystemTM demonstrated at the recent COMPAMED event

We are delighted to share that, alongside our partners BYTEC Medizintechnik GmbH, the next generation CorFlow Infusion System was demonstrated at the Compamed exhibition. BYTEC has been developing and manufacturing high-tech medical devices in diagnostics, surgery and therapy for more than 30 years. 

The system created a lot of interest from delegates from within Europe as well as from further afield. For further information please contact us!

  • March 1, 2024
New ESC Guidelines on the Management of Acute Coronary Syndromes

At the end of August 2023, the European Society of Cardiology released the new guidelines on the management of acute coronary syndromes, combining for the first time the previous STEMI and ACS guidelines. Of note, the experts stated: 

“Microvascular obstruction associated with pPCI represents an unmet clinical need in patients with ACS. Development of therapies for the prevention and treatment of MVO is urgently needed.”

Download the guidelines
  • Octomber 23, 2019
FDA grants “Breakthrough Device Designation” to CorFlow Therapeutics to expedite clinical development and regulatory review of its CoFI (COF-fee) System
AAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG today announced that the FDA has designated the company’s CoFI (Controlled Flow Infusion) System as a “Breakthrough Device” with a broad indication-for-use statement: “The CoFI System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a platform for controlled infusion of therapeutic agents into the microcirculation with or without vessel occlusion.”
View Press Release
  • September 12, 2018
CorFlow Completes USD 9.7M in Seed Funding
BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG today announced that the company has completed the 2nd close of its Seed+ financing round.
View Press Release
Contact us

CorFlow is developing a medical device that will be the first to diagnose MVO in real-time during PCI and serve as a treatment platform in the cath lab.

Twitter Linkedin
Who we are
Clinical
News
Our Office
  • +41 41 399 18 00
  • CorFlow Therapeutics AG Neuhofstrasse 3d 6340 Baar, Switzerland
  • contact@corflow.ch

The CoFI-System is not approved in the United States of America.  It is an investigational device limited by federal law to investigational use and is not available for commercial distribution.

VAT:CHE 320.873.257 MWST

© 2023 Corflow. All Rights Reserved.

Cookie Policy | Privacy Policy | Site Map | Impressum